A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

NCT04868162 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: MRG003
DRUG: MRG003+HX008

Sponsor

Shanghai Miracogen Inc.